BJH:地塞米松介导的 Notch 信号抑制阻断了白血病和间充质基质细胞的相互作用

2021-11-23 MedSci原创 MedSci原创

急性髓系白血病 (AML) 是一种血液系统恶性肿瘤,其特征是预后不良。骨髓间充质基质细胞 (BM MSC) 支持白血病细胞预防化疗诱导的细胞凋亡。

急性髓系白血病 (AML) 是一种血液系统恶性肿瘤,其特征是预后不良。骨髓间充质基质细胞 (BM MSC) 支持白血病细胞预防化疗诱导的细胞凋亡。地塞米松对涉及骨髓间充质干细胞和白血病细胞相互作用的复杂骨髓壁龛的影响以及这如何影响治疗结果没有研究

因此,国外一研究团队试图对此进行调查,以提高对白血病 BM 生态位相关信号的理解,并最终确定新颖且有效的抗白血病治疗策略。在体外和体内详细研究了 AML 细胞与 BM MSC 的串扰分析以及如何在治疗水平上利用它们的相互作用。

他们使用了先前所描述的鼠AML细胞系,C1498和MSCS从控制分离[野生型(WT)的MSC]和白血病小鼠(AML的MSC )。从模拟与AML1-ETO9aMLL-AF9肿瘤融合蛋白(分别为 t(8;21)(q22;q22) 和 t(9;11)(p22;q23) 的产物)相关的人类 AML 亚型的小鼠中分离出 MSC 。将 C1498 细胞和 WT-/AML MSCs 直接接触或通过 transwell 插入物分开。与没有接受 MSC 支持的细胞相比,WT MSC 显着支持 C1498 细胞的增殖

鼠和人急性髓性白血病 (AML) 间充质基质细胞 (MSC) 支持白血病细胞的增殖

他们假设地塞米松介导的对 AML MSC 中 Notch 信号传导的阻断可能解释了在 AML 患者中观察到的治疗益处。为了验证假设,将MLL-AF9白血病细胞和 WT 或 AML MSC 共培养并用载体(磷酸盐缓冲盐水,PBS)或不同剂量的地塞米松处理。

地塞米松在体外对急性髓系白血病 (AML) 细胞和 AML-间充质基质细胞 (MSC) 相互作用的作用

为了验证使用鼠 AML 细胞系 C1498 和原代鼠 MSC 获得的结果并证明结果不是特定于共培养系统的结果,她们使用了永生化人类 MSC 和人类 AML 细胞系 Kasumi-1,为了验证原代和永生化 MSC 的表型具有可比性,检查了它们的表面标志物和分化为脂肪细胞、软骨细胞和骨细胞的能力。为了在分子水平上表征 AML MSC,从非白血病(WT MSC)和MLL-AF9白血病小鼠中分选了 MSC,并使用 RNA 微阵列进行了基因表达谱分析。

急性髓性白血病 (AML) 间充质基质细胞 (MSC) 的分子特征

他们评估了地塞米松对MLL-AF9转基因白血病小鼠白血病进展和存活的治疗效果,以及地塞米松是否也影响了体内Notch 信号传导。移植了MLL-AF9-将白血病细胞表达到 C57BL/6 (WT) 小鼠中,随后每周一次施用 0·1 mg/kg 地塞米松或载体 (PBS)。

地塞米松对急性髓系白血病 (AML) 细胞和 AML-间充质基质细胞 (MSC)体内相互作用的作用

他们的数据,特别是在 AML MSC 中,证明了 Notch 标志基因集的富集和 Notch 信号传导的激活。在治疗上,地塞米松治疗消除了白血病细胞和 AML MSC 的相互作用并阻断了 Notch 信号传导。Notch抑制剂(GSI-XII)进一步增强了地塞米松的治疗效果。

地塞米松治疗干扰的白血病和急性髓系白血病(AML)-间充质基质细胞(MSC)相互作用

研究证明了源自白血病的 MSC (AML MSC) 和健康供体 (HD MSC) 之间的功能差异。白血病和 AML 间充质干细胞的直接相互作用对于影响 AML 细胞增殖是必不可少的。进一步确定了 Notch 表达及其在 AML MSC 中激活的重要作用,有助于增强 AML 细胞的增殖。AML MSC中细胞内Notch结构域(Notch ICN)的过表达增强了AML细胞的增殖。从治疗的角度来看,地塞米松治疗阻碍了 AML MSC 中的 Notch 信号传导,导致 AML 细胞增殖减少。

同时,Notch 抑制剂仅对白血病细胞有轻微影响,但强烈影响了 AML MSC 中的 Notch 信号传导并取消了它们对 AML 细胞的细胞保护功能。在体内,地塞米松治疗阻碍了 AML MSC 中的 Notch 信号传导,导致 AML MSC 数量减少并提高了白血病小鼠的存活率。

总之,使用地塞米松或 Notch 抑制剂靶向白血病细胞和 AML MSC 的相互作用可能会进一步改善 AML 患者的治疗结果

 

原始出处:

Ahmed, H.M.M., Nimmagadda, S.C., Al-Matary, Y.S., Fiori, M., May, T., Frank, D., Patnana, P.K., Récher, C., Schliemann, C., Mikesch, J.-H., Koenig, T., Rosenbauer, F., Hartmann, W., Tuckermann, J., Dührsen, U., Lanying, W., Dugas, M., Opalka, B., Lenz, G. and Khandanpour, C. (2021), Dexamethasone-mediated inhibition of Notch signalling blocks the interaction of leukaemia and mesenchymal stromal cells. Br J Haematol. https://doi.org/10.1111/bjh.17940

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1710296, encodeId=7d981e1029600, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Sun Oct 09 04:27:49 CST 2022, time=2022-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909323, encodeId=7865190932325, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sun Dec 12 00:27:49 CST 2021, time=2021-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757240, encodeId=ccc71e57240ae, content=<a href='/topic/show?id=103b421e0e8' target=_blank style='color:#2F92EE;'>#基质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42170, encryptionId=103b421e0e8, topicName=基质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=281337296540, createdName=ms7899726347904398, createdTime=Wed Feb 23 03:27:49 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373804, encodeId=fc9613e38047b, content=<a href='/topic/show?id=eb3b129e01d' target=_blank style='color:#2F92EE;'>#Notch#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12970, encryptionId=eb3b129e01d, topicName=Notch)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ece5364, createdName=karmond, createdTime=Thu Nov 25 07:27:49 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471692, encodeId=fd6214e169214, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Thu Nov 25 07:27:49 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487506, encodeId=910b148e50631, content=<a href='/topic/show?id=ba951352387' target=_blank style='color:#2F92EE;'>#OTC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13523, encryptionId=ba951352387, topicName=OTC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b36f8313624, createdName=ymljack, createdTime=Thu Nov 25 07:27:49 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073239, encodeId=2c1a10e3239e9, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dfbe5502857, createdName=ms4000000575043187, createdTime=Tue Nov 23 17:10:50 CST 2021, time=2021-11-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1710296, encodeId=7d981e1029600, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Sun Oct 09 04:27:49 CST 2022, time=2022-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909323, encodeId=7865190932325, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sun Dec 12 00:27:49 CST 2021, time=2021-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757240, encodeId=ccc71e57240ae, content=<a href='/topic/show?id=103b421e0e8' target=_blank style='color:#2F92EE;'>#基质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42170, encryptionId=103b421e0e8, topicName=基质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=281337296540, createdName=ms7899726347904398, createdTime=Wed Feb 23 03:27:49 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373804, encodeId=fc9613e38047b, content=<a href='/topic/show?id=eb3b129e01d' target=_blank style='color:#2F92EE;'>#Notch#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12970, encryptionId=eb3b129e01d, topicName=Notch)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ece5364, createdName=karmond, createdTime=Thu Nov 25 07:27:49 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471692, encodeId=fd6214e169214, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Thu Nov 25 07:27:49 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487506, encodeId=910b148e50631, content=<a href='/topic/show?id=ba951352387' target=_blank style='color:#2F92EE;'>#OTC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13523, encryptionId=ba951352387, topicName=OTC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b36f8313624, createdName=ymljack, createdTime=Thu Nov 25 07:27:49 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073239, encodeId=2c1a10e3239e9, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dfbe5502857, createdName=ms4000000575043187, createdTime=Tue Nov 23 17:10:50 CST 2021, time=2021-11-23, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1710296, encodeId=7d981e1029600, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Sun Oct 09 04:27:49 CST 2022, time=2022-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909323, encodeId=7865190932325, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sun Dec 12 00:27:49 CST 2021, time=2021-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757240, encodeId=ccc71e57240ae, content=<a href='/topic/show?id=103b421e0e8' target=_blank style='color:#2F92EE;'>#基质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42170, encryptionId=103b421e0e8, topicName=基质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=281337296540, createdName=ms7899726347904398, createdTime=Wed Feb 23 03:27:49 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373804, encodeId=fc9613e38047b, content=<a href='/topic/show?id=eb3b129e01d' target=_blank style='color:#2F92EE;'>#Notch#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12970, encryptionId=eb3b129e01d, topicName=Notch)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ece5364, createdName=karmond, createdTime=Thu Nov 25 07:27:49 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471692, encodeId=fd6214e169214, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Thu Nov 25 07:27:49 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487506, encodeId=910b148e50631, content=<a href='/topic/show?id=ba951352387' target=_blank style='color:#2F92EE;'>#OTC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13523, encryptionId=ba951352387, topicName=OTC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b36f8313624, createdName=ymljack, createdTime=Thu Nov 25 07:27:49 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073239, encodeId=2c1a10e3239e9, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dfbe5502857, createdName=ms4000000575043187, createdTime=Tue Nov 23 17:10:50 CST 2021, time=2021-11-23, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1710296, encodeId=7d981e1029600, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Sun Oct 09 04:27:49 CST 2022, time=2022-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909323, encodeId=7865190932325, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sun Dec 12 00:27:49 CST 2021, time=2021-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757240, encodeId=ccc71e57240ae, content=<a href='/topic/show?id=103b421e0e8' target=_blank style='color:#2F92EE;'>#基质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42170, encryptionId=103b421e0e8, topicName=基质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=281337296540, createdName=ms7899726347904398, createdTime=Wed Feb 23 03:27:49 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373804, encodeId=fc9613e38047b, content=<a href='/topic/show?id=eb3b129e01d' target=_blank style='color:#2F92EE;'>#Notch#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12970, encryptionId=eb3b129e01d, topicName=Notch)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ece5364, createdName=karmond, createdTime=Thu Nov 25 07:27:49 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471692, encodeId=fd6214e169214, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Thu Nov 25 07:27:49 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487506, encodeId=910b148e50631, content=<a href='/topic/show?id=ba951352387' target=_blank style='color:#2F92EE;'>#OTC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13523, encryptionId=ba951352387, topicName=OTC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b36f8313624, createdName=ymljack, createdTime=Thu Nov 25 07:27:49 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073239, encodeId=2c1a10e3239e9, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dfbe5502857, createdName=ms4000000575043187, createdTime=Tue Nov 23 17:10:50 CST 2021, time=2021-11-23, status=1, ipAttribution=)]
    2021-11-25 karmond
  5. [GetPortalCommentsPageByObjectIdResponse(id=1710296, encodeId=7d981e1029600, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Sun Oct 09 04:27:49 CST 2022, time=2022-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909323, encodeId=7865190932325, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sun Dec 12 00:27:49 CST 2021, time=2021-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757240, encodeId=ccc71e57240ae, content=<a href='/topic/show?id=103b421e0e8' target=_blank style='color:#2F92EE;'>#基质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42170, encryptionId=103b421e0e8, topicName=基质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=281337296540, createdName=ms7899726347904398, createdTime=Wed Feb 23 03:27:49 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373804, encodeId=fc9613e38047b, content=<a href='/topic/show?id=eb3b129e01d' target=_blank style='color:#2F92EE;'>#Notch#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12970, encryptionId=eb3b129e01d, topicName=Notch)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ece5364, createdName=karmond, createdTime=Thu Nov 25 07:27:49 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471692, encodeId=fd6214e169214, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Thu Nov 25 07:27:49 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487506, encodeId=910b148e50631, content=<a href='/topic/show?id=ba951352387' target=_blank style='color:#2F92EE;'>#OTC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13523, encryptionId=ba951352387, topicName=OTC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b36f8313624, createdName=ymljack, createdTime=Thu Nov 25 07:27:49 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073239, encodeId=2c1a10e3239e9, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dfbe5502857, createdName=ms4000000575043187, createdTime=Tue Nov 23 17:10:50 CST 2021, time=2021-11-23, status=1, ipAttribution=)]
    2021-11-25 ylz8405
  6. [GetPortalCommentsPageByObjectIdResponse(id=1710296, encodeId=7d981e1029600, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Sun Oct 09 04:27:49 CST 2022, time=2022-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909323, encodeId=7865190932325, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sun Dec 12 00:27:49 CST 2021, time=2021-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757240, encodeId=ccc71e57240ae, content=<a href='/topic/show?id=103b421e0e8' target=_blank style='color:#2F92EE;'>#基质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42170, encryptionId=103b421e0e8, topicName=基质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=281337296540, createdName=ms7899726347904398, createdTime=Wed Feb 23 03:27:49 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373804, encodeId=fc9613e38047b, content=<a href='/topic/show?id=eb3b129e01d' target=_blank style='color:#2F92EE;'>#Notch#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12970, encryptionId=eb3b129e01d, topicName=Notch)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ece5364, createdName=karmond, createdTime=Thu Nov 25 07:27:49 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471692, encodeId=fd6214e169214, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Thu Nov 25 07:27:49 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487506, encodeId=910b148e50631, content=<a href='/topic/show?id=ba951352387' target=_blank style='color:#2F92EE;'>#OTC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13523, encryptionId=ba951352387, topicName=OTC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b36f8313624, createdName=ymljack, createdTime=Thu Nov 25 07:27:49 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073239, encodeId=2c1a10e3239e9, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dfbe5502857, createdName=ms4000000575043187, createdTime=Tue Nov 23 17:10:50 CST 2021, time=2021-11-23, status=1, ipAttribution=)]
    2021-11-25 ymljack
  7. [GetPortalCommentsPageByObjectIdResponse(id=1710296, encodeId=7d981e1029600, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Sun Oct 09 04:27:49 CST 2022, time=2022-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909323, encodeId=7865190932325, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sun Dec 12 00:27:49 CST 2021, time=2021-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757240, encodeId=ccc71e57240ae, content=<a href='/topic/show?id=103b421e0e8' target=_blank style='color:#2F92EE;'>#基质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42170, encryptionId=103b421e0e8, topicName=基质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=281337296540, createdName=ms7899726347904398, createdTime=Wed Feb 23 03:27:49 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373804, encodeId=fc9613e38047b, content=<a href='/topic/show?id=eb3b129e01d' target=_blank style='color:#2F92EE;'>#Notch#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12970, encryptionId=eb3b129e01d, topicName=Notch)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ece5364, createdName=karmond, createdTime=Thu Nov 25 07:27:49 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471692, encodeId=fd6214e169214, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Thu Nov 25 07:27:49 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487506, encodeId=910b148e50631, content=<a href='/topic/show?id=ba951352387' target=_blank style='color:#2F92EE;'>#OTC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13523, encryptionId=ba951352387, topicName=OTC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b36f8313624, createdName=ymljack, createdTime=Thu Nov 25 07:27:49 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073239, encodeId=2c1a10e3239e9, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dfbe5502857, createdName=ms4000000575043187, createdTime=Tue Nov 23 17:10:50 CST 2021, time=2021-11-23, status=1, ipAttribution=)]
    2021-11-23 ms4000000575043187

    不错

    0

相关资讯

Lancet Haemat:全反式维甲酸+大剂量地塞米松或可成为原发性免疫性血小板减少症的新一线疗法!

全反式维甲酸+大剂量地塞米松或可成为原发性免疫性血小板减少症的新一线疗法

IBD: 围手术期使用地塞米松可以减少炎症性肠病患者手术后的过度炎症反应和肠梗阻的发生

尽管生物制剂被广泛用于治疗炎症性肠病 (IBD),但手术仍然是很大一部分患者的主要治疗选择。

患者输液20分钟后死亡!输的是头孢与地塞米松

在搜「配伍禁忌」时,留意到一个很有意思的问题:都是头孢,头孢比罗酯、头孢曲松能跟地塞米松同瓶配伍,就「头孢呋辛」不行。

J Arthroplasty:全髋关节置换术后追加使用地塞米松可提供持续的疼痛缓解和炎症控制

全髋关节置换术(THA)中地塞米松的最佳剂量方案尚不清楚。近日,一项随机试验对比了全髋关节置换术中1剂量、2剂量和3剂量地塞米松的效果,研究结果已发表于J Arthroplasty。

J Proteome Res:全身地塞米松给药与鼓膜内地塞米松给药对外淋巴蛋白组的影响

糖皮质激素可通过口服途径全身给药或通过耳内注射局部给药,是突发性感音神经性听力损失的一线治疗选择

Reg Anesth Pain Med:选择性全膝关节置换术的局部浸润镇痛中加入地塞米松的效果

全膝关节置换术伴有明显的疼痛,有效的镇痛有利于提高病人的满意度和功能效果。研究表明,地塞米松可能对局部麻醉的作用有促进作用,但这种作用在加入膝关节置换术患者的局部浸润镇痛(LIA)混合物中,还没有得到

拓展阅读

激素退烧到底是用「地塞米松」还是「甲强龙」?

临床上,如何正确退热?何时使用退烧药?

Haematologica | 卡非佐米、沙利度胺和地塞米松用于多发性骨髓瘤复发或难治患者:ALLG MM018/AMN002 单臂多中心II期研究的最终报告

该研究旨在评估固定疗程的卡非佐米、沙利度胺和地塞米松(KTd)在1-3线治疗后的MM复发或难治患者中的安全性和有效性,卡非佐米、沙利度胺和地塞米松联合使用在MM复发或难治患者中表现良好的耐受性和疗效。

【血液学】Isatuximab+泊马度胺+地塞米松治疗RRMM的3期研究最终OS结果

Isa-Pd在随访约52个月后仍然有效且耐受性良好,使复发/难治性多发性骨髓瘤患者的中位总生存期延长6.9个月,有临床意义。

Haematologica | 塞利尼索 + 达雷木单抗 + 硼替佐米 + 地塞米松四联疗法治疗复发难治性多发性骨髓瘤的II期临床研究

该研究旨在评估塞利尼索、达雷木单抗、硼替佐米和地塞米松四联疗法在复发难治性骨髓瘤患者中的疗效和安全性,研究未达到主要终点,但在早期复发患者中显示出较好的疗效,可能提供一种有前景的治疗选择。

【AJH】达雷妥尤单抗+伊沙佐米+地塞米松治疗来那度胺暴露二线RRMM的2期DARIA研究结果

前瞻性、开放标签、2期DARIA研究纳入一线接受来那度胺为基础诱导方案的MM患者,二线给予达雷妥尤单抗-伊沙佐米-地塞米松(Dara-Ixa-dex)治疗。

【Haematologica】塞利尼索+达雷妥尤单抗+Vd治疗RRMM的II期研究

西班牙骨髓瘤工作组学者假设,在达雷妥尤单抗、硼替佐米、地塞米松的基础上加入塞利尼索可以改善复发/难治性多发性骨髓瘤的疗效,并开展一项II期研究评估该四药方案治疗RRMM的疗效和安全性。

2023 NICE 介入程序指南:当干细胞移植不适合时,达雷木单抗联合来那度胺和地塞米松治疗未经治疗的多发性骨髓瘤 [TA917]

英国国家卫生与临床优化研究所(NICE,National Institute for Health and Clinical Excellence) · 2023-10-25

2023 NICE 技术鉴定指导意见:伊沙佐米联合来那度胺和地塞米松治疗复发或难治性多发性骨髓瘤[TA870]

英国国家卫生与临床优化研究所(NICE,National Institute for Health and Clinical Excellence) · 2023-02-22

2022 NICE 技术鉴定指南:地塞米松玻璃体内植入物治疗糖尿病性黄斑水肿 [TA824]

英国国家卫生与临床优化研究所(NICE,National Institute for Health and Clinical Excellence) · 2022-09-14